Stocks Down Under Videos
Get a 3-month FREE TRIAL to CONCIERGE now!
Concierge gives you timely BUY and SELL alerts on ASX-listed stocks
Unicycive Therapeutics (Nasdaq:UNCY) has big plans for its lead candidate OLC
January 15, 2026
Unicycive Therapeutics
Unicycive Therapeutics (Nasdaq:UNCY)
Unicycive Therapeutics is a clinical-stage biotech company based in Los Altos, CA. The company’s lead candidate is oxylanthanum carbonate (OLC), a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
In this interview, we talk to UNCY’s CEO Dr Shalabh Gupta about the company’s plans to resubmit its New Drug Application for OLC, the superiority of this drug to other treatments for hyperphosphatemia the potential market and the company’s commercialisation plans.
Check out UNCY’ Phase 2 clinical trial results HERE!
Looking for the Best Life Sciences stocks to invest in right now?
